Orion Porfolio Solutions LLC Sells 6,370 Shares of Danaher Corporation $DHR

Orion Porfolio Solutions LLC reduced its holdings in Danaher Corporation (NYSE:DHR) by 8.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 68,544 shares of the conglomerate’s stock after selling 6,370 shares during the quarter. Orion Porfolio Solutions LLC’s holdings in Danaher were worth $13,540,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in DHR. Ceredex Value Advisors LLC boosted its stake in Danaher by 1.6% during the second quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after buying an additional 3,862 shares during the period. Chicago Capital LLC raised its stake in Danaher by 11.6% in the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after buying an additional 1,391 shares in the last quarter. Weitz Investment Management Inc. boosted its position in Danaher by 6.1% during the second quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock valued at $104,094,000 after purchasing an additional 30,300 shares in the last quarter. UniSuper Management Pty Ltd grew its holdings in Danaher by 1.6% in the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock worth $34,954,000 after purchasing an additional 2,667 shares during the last quarter. Finally, Nvwm LLC grew its stake in shares of Danaher by 20.4% during the second quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after acquiring an additional 1,204 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the sale, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This represents a 13.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 30,248 shares of company stock valued at $6,609,663. 11.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. TD Cowen boosted their price objective on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. HSBC lifted their price objective on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. The Goldman Sachs Group initiated coverage on shares of Danaher in a research report on Tuesday, December 9th. They set a “buy” rating and a $265.00 price target on the stock. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a report on Tuesday, September 2nd. Finally, Robert W. Baird set a $247.00 price objective on shares of Danaher in a research note on Wednesday, October 22nd. Twenty-one analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $246.79.

Danaher Trading Down 2.4%

Shares of DHR stock opened at $226.70 on Monday. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The firm has a market capitalization of $160.13 billion, a PE ratio of 46.74, a P/E/G ratio of 4.39 and a beta of 0.89. The business’s fifty day moving average price is $218.51 and its 200 day moving average price is $205.90. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.Danaher’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.71 earnings per share. As a group, sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s payout ratio is presently 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.